huIL5 Mouse
제품명
huIL5 Mouse
제품 ID
C001813
품종 계통
C57BL/6NCya-Il5tm1(hIL5)/Cya
Backgroud
C57BL/6NCya
상태
이 마우스 계통을 논문에서 사용할 경우, “huIL5 Mouse (카탈로그 번호 C001813)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
유전자명
유전자 별칭
EDF, TRF, IL-5
NCBI ID
염색체
Chr 5
MGI ID
Datasheet
품종 계통 설명
Interleukin-5 (IL-5) is a cytokine secreted by Th2 CD4+ T cells, mast cells, and type 2 innate lymphoid cells (ILC2s). It plays a pivotal role in regulating the proliferation, differentiation, activation, and survival of eosinophils [1]. The IL5 gene is located within the 5q31 region of human chromosome 5, clustered alongside other Th2 cytokine genes such as IL4 and IL13, and is co-regulated by transcription factors including GATA3 [2]. By binding to the IL-5 receptor alpha chain (IL-5Rα), IL-5 activates signaling pathways like JAK2-STAT5, thereby modulating eosinophil-associated immune responses [1-2]. Aberrant IL-5 expression is closely linked to various eosinophil-related disorders, including asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), hypereosinophilic syndrome, and allergic rhinitis, making the IL-5/IL-5Rα axis a prominent therapeutic target. Consequently, several antibody drugs targeting IL-5 or IL-5Rα, such as Mepolizumab and Benralizumab, have been approved or are currently under clinical investigation [3-4].
The huIL5 mouse is a humanized model generated by replacing the mouse Il5 gene sequence (from the start codon to the stop codon) with the corresponding human IL5 sequence via in situ substitution. This model is highly valuable for studying eosinophilic diseases (e.g., asthma, CRSwNP, and hypereosinophilic syndrome), allergic inflammatory immune regulation, and Th2 immune responses. Furthermore, it serves as a robust platform for the development of IL-5-targeted therapeutics.
Reference
Takatsu K. Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(8):463-485.
Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, Lee NA. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy. 2010;40(4):563-575.
Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM). Lancet. 2012;380(9842):651-659.
FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma. Lancet. 2016;388(10056):2128-2141.
변형 전략
The sequences from the start codon to the stop codon of the endogenous mouse Il5 gene were replaced with the sequences from the start codon to the stop codon of the human IL5 gene.
Figure 1. Gene editing strategy for huIL5 mice.
응용 분야
Research on asthma and eosinophilic airway diseases;
Studies on chronic rhinosinusitis with nasal polyps (CRSwNP) and hypereosinophilic syndrome;
Investigation of allergic rhinitis and atopic dermatitis;
Mechanistic studies of allergic inflammation;
Preclinical evaluation of IL-5-targeted therapeutics;
In vivo validation of immunotherapies;
Cytokine signaling pathway research.
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.